



Action of Varespladib (LY-315920), a Phospholipase A₂ Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of *Lachesis muta rhombeata* (South-American Bushmaster) Venom

Pamella G. Gutierrez¹, Diego R. Pereira¹, Nataly L. Vieira¹, Lilian F. Arantes², Nelson J. Silva Jr.³, Kristian A. Torres-Bonilla⁴, Stephen Hyslop⁴, Karen Moraes-Zani⁵, Rosa M. B. Nogueira¹, Edward G. Rowan⁶ and Rafael S. Floriano^{1*}

OPEN ACCESS

Edited by:

Delavar Shahbazzadeh,
Pasteur Institute of Iran (PII), Iran

Reviewed by:

Manuela Berto Pucca,
Federal University of Roraima, Brazil
Kamran Pooshang Bagheri,
Pasteur Institute of Iran (PII), Iran
Roghieh Mirzazadeh,
Pasteur Institute of Iran (PII), Iran

*Correspondence:

Rafael S. Floriano
rafael@unoeste.br

Specialty section:

This article was submitted to
Translational Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 10 November 2021

Accepted: 09 December 2021

Published: 12 January 2022

Citation:

Gutierrez PG, Pereira DR, Vieira NL, Arantes LF, Silva Jr. NJ, Torres-Bonilla KA, Hyslop S, Moraes-Zani K, Nogueira RMB, Rowan EG and Floriano RS (2022) Action of Varespladib (LY-315920), a Phospholipase A₂ Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of *Lachesis muta rhombeata* (South-American Bushmaster) Venom. *Front. Pharmacol.* 12:812295. doi: 10.3389/fphar.2021.812295

¹Laboratory of Toxinology and Cardiovascular Research, University of Western São Paulo, Presidente Prudente, Brazil, ²Graduate Program in Zootechnics, Rural Federal University of Pernambuco, Recife, Brazil, ³Graduate Program in Environmental Sciences and Health, School of Medical, Pharmaceutical and Biomedical Sciences, Pontifical Catholic University of Goiás, Goiânia, Brazil, ⁴Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil, ⁵Laboratory of Herpetology, Butantan Institute, São Paulo, Brazil, ⁶Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom

Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A₂ (PLA₂). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA₂-dependent effects produced by snake venoms. In this study, we examined the action of VPL on the coagulant, haemorrhagic and enzymatic activities of *Lachesis muta rhombeata* (South-American bushmaster) venom. Conventional colorimetric enzymatic assays were performed for PLA₂, caseinolytic and esterase activities; *in vitro* coagulant activities for prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed in rat citrated plasma through a quick timer coagulometer, whereas the dimensions of haemorrhagic haloes obtained after i.d. injections of venom in Wistar rats were determined using ImageJ software. Venom (1 mg/ml) exhibited accentuated enzymatic activities for proteases and PLA₂ *in vitro*, with VPL abolishing the PLA₂ activity from 0.01 mM; VPL did not affect caseinolytic and esterase activities at any tested concentrations (0.001–1 mM). In rat citrated plasma *in vitro*, VPL (1 mM) alone efficiently prevented the venom (1 mg/ml)-induced procoagulant disorder associated to extrinsic (PT) pathway, whereas its association with a commercial antivenom successfully prevented changes in both intrinsic (aPTT) and extrinsic (PT) pathways; commercial antivenom by itself failed to avoid the procoagulant disorders by this venom. Venom (0.5 mg/kg)-induced hemorrhagic activity was slightly reduced by VPL (1 mM) alone or combined with antivenom (antivenom:venom ratio 1:3 'v/w') in rats, with antivenom alone producing no protective action on this parameter. In

conclusion, VPL does not inhibit other major enzymatic groups of *L. m. rhombeata* venom, with its high PLA₂ antagonize activity efficaciously preventing the venom-induced coagulation disturbances.

Keywords: Viperidae snake, phospholipase A₂ (PLA₂), coagulating activity, haemorrhage, varespladib, antivenom, neutralization

INTRODUCTION

Snakes of *Lachesis* genus are represented by three species found in Central America (*L. stenophrys*, *L. melanocephala*, and *L. acrochorda*) and one in South America (*L. muta*), with the latter being recognized as two subspecies distributed in the Amazon river basin (= *L. muta muta*) and Atlantic rainforest (= *L. muta rhombeata*) in Brazil (Costa and Bérnils, 2018; Nogueira et al., 2019; Diniz-Sousa et al., 2020). Together, these snakes are responsible by the second most frequent cases of snakebites in Americas, being exceeded only by *Bothrops* snakes (Magalhães et al., 2019; Diniz-Sousa et al., 2020).

Envenomation by *Lachesis* spp. is characterized by intense local pain, oedema and necrosis (Damico et al., 2006; Ferreira et al., 2009; Damico et al., 2012), systemic myotoxicity (Fuly et al., 2000; Fuly et al., 2003; Damico et al., 2006), renal failure (Damico et al., 2007), haemorrhage and coagulopathy (Sánchez et al., 1987; Sánchez et al., 1991; Sánchez et al., 1995; Fuly et al., 1997; Rucavado et al., 1999; Estêvão-Costa et al., 2000; Torres-Huaco et al., 2013), including severe cardiovascular disorders (Diniz and Oliveira, 1992; Giovanni-De-Simone et al., 1997; Dias et al., 2016a; Dias et al., 2016b). Such effects have been associated predominantly with the presence of phospholipases A₂ (PLA₂) (Cordeiro et al., 2015; Diniz-Sousa et al., 2018), metalloproteases (Cordeiro et al., 2018) and serine proteases (Wiesel et al., 2019), including biologically active peptides (Graham et al., 2005; Soares et al., 2005; Sanz et al., 2008; Pla et al., 2013; Pinheiro-Júnior et al., 2018), in these venoms.

Polyvalent antivenom (=anti-*Bothrops/Lachesis* serum) therapies comprise the main therapeutic options to treat the systemic envenomation by *Lachesis* snakes (Madrigal et al., 2017; Solano et al., 2018). Recently, several studies have demonstrated the value of varespladib, a PLA₂ inhibitor drug (Lewin et al., 2016; Salvador et al., 2019), concerning its suppressive action on the biological effects of Elapidae and Viperidae venoms (Bittenbinder et al., 2018; Lewin et al., 2018; Wang et al., 2018; Zinenko et al., 2020; Gutiérrez et al., 2020a), including their toxins (Bryan-Quirós et al., 2019; Salvador et al., 2021). However, there are not reports about the action of varespladib, as a stand-alone therapy and/or combined with antivenoms, on the toxic effects caused by *Lachesis* venoms. In the present study, we have investigated the efficiency of this drug on some aspects of the envenomation by *Lachesis muta rhombeata* venom using *in vitro* and *in vivo* approaches for enzymatic, coagulant and haemorrhagic activities of this venom. We have also assessed an eventual synergic mechanism of action by varespladib when combined with a commercial antivenom used to treat envenomations by *Lachesis* in Brazil.

MATERIALS AND METHODS

Reagents

Varespladib (LY-315920) was obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, United States) and anti-*Bothrops/Lachesis* serum was from Butantan Institute (São Paulo, SP, Brazil); varespladib was dissolved in DMSO prior to use, whereas the antivenom was provided ready for injection and maintained under refrigeration. Azocasein (A2765), Na-Benzoyl-DL-arginine 4-nitroanilide hydrochloride (B4875) and 4-nitro-3-octanoyloxy-benzoic acid (N1646) substrates were also from Sigma-Aldrich Chemical Co. (St. Louis, MO, United States). *Lachesis m. rhombeata* venom was provided by Center for Biological Studies and Research of the Pontifical Catholic University of Goiás (PUC Goiás, Goiânia, GO, Brazil) through Dr Nelson J. Silva Jr. A lyophilized pool of venom obtained from one female adult snake was stored at -20°C and dissolved in ultrapure water prior to use.

Animals

Wistar rats (300–350 g; 2–3 months old) obtained from Central Bioterium of the University of Western São Paulo (UNOESTE, Presidente Prudente, SP, Brazil) were housed in plastic cages (3 animals/cage) with a wood-shaving substrate, at 23 ± 1°C on a 12-h light/dark cycle with lights on at 6 a.m. The animals had free access to food and water. The experimental procedures were approved by an institutional Committee for Ethics in Animal Use (CEUA/UNOESTE, Protocol No. 6713/2021) and were done according to the general ethical guidelines for animal use established by the Brazilian Society of Laboratory Animal Science (SBCAL) and Brazilian Federal Law No. 11.794 of October 8, 2008, in conjunction with the guidelines for animal experiments established by the Brazilian National Council for Animal Experimentation (CONCEA).

Phospholipase A₂ (PLA₂) Activity

PLA₂ activity was assayed essentially as described elsewhere (Carregari et al., 2013). The standard assay mixture contained 200 µl of buffer (10 mM Tris-HCl, 10 mM CaCl₂ and 100 mM NaCl, pH 8.0), 20 µl of substrate (3 mM 4-nitro-3-octanoyloxy-benzoic acid) and 20 µl of sample [venom alone (1 mg/ml) or venom (1 mg/ml) pre-incubated (for 30 min at 37°C) with varespladib (0.001–1 mM)] in a final volume of 240 µl. After adding sample, the mixture was incubated for 30 min at 37°C, with one unit of enzymatic activity being defined as an increase in absorbance of 0.001/min at 425 nm. All assays were done in triplicate with readings at 60-s intervals using a SpectraMax 340

multiwell plate reader (Molecular Devices, San Jose, CA, United States).

Caseinolytic Activity


Caseinolytic activity was determined through colorimetric assay in a SpectraMax 340 multiwell plate reader (Molecular Devices, San Jose, CA, United States) using Azocasein as substrate, essentially as described elsewhere (Torres-Bonilla et al., 2020). The standard assay mixture contained 90 μ l of substrate (212 mM Azocasein), 10 μ l of reaction buffer (0.05 M Tris-HCl, 1 mM CaCl₂, pH 8.0) and 10 μ l of sample [venom alone (1 mg/ml) or venom (1 mg/ml) pre-incubated (for 30 min at 37°C) with varespladib (0.001–1 mM)] in a final volume of 110 μ l. The mixture was incubated for 90 min at 37°C and then the reaction was terminated adding 200 μ l of TCA 5% for 5 min at room temperature; the mixture was centrifuged (5 min at 8,000 g) and 150 μ l of supernatant was transferred to the multiwell plate containing the same volume of NaOH (0.5 M). Finally, the absorbance was read at 440 nm via endpoint mode, with one activity unit being defined as an increase of absorbance of 0.001/min.

Esterase Activity

Esterase activity was assayed essentially as described by (Erlanger et al., 1961) and adapted by (Torres-Bonilla et al., 2020). The standard assay mixture contained 200 μ l of substrate (100 mM N α -Benzoyl-DL-arginine 4-nitroanilide hydrochloride), 50 μ l of reaction buffer (10 mM Tris-HCl, 10 mM CaCl₂, 100 mM NaCl, pH 8.0), 15 μ l of ultrapure water and 5 μ l of sample [venom alone (1 mg/ml) or venom (1 mg/ml) pre-incubated (for 30 min at 37°C) with varespladib (0.001–1 mM)] in a final volume of 270 μ l. The mixture was incubated for 30 min at 37°C in a multiwell plate and then read under an absorbance at $\lambda = 410$ nm via endpoint mode, with one activity unit being defined as an increase of absorbance of 0.001/min.

Coagulant Activity

Coagulant activity was performed using Labtest[®] commercial kits (Labtest Diagnóstica S.A., Lagoa Santa, MG, Brasil) performed in a quick timer Coagmaster 4.0 (Wama Diagnóstica Produtos para Laboratórios, São Carlos, SP, Brazil). Wistar rats were anesthetized by a non-lethal dose (1.8 mg/kg, i.p.) of thiopental (Cristália[®], São Paulo, SP, Brazil) and, subsequently, subjected to intracardiac puncture in order to obtain blood samples using BD Vacutainer[®] Citrate Tubes with 3.2% buffered sodium citrate solution at an anticoagulant: blood ratio of 1:10 (v/v); after this procedure, the animals were euthanased in saturated atmosphere with CO₂. Blood samples were centrifuged (2,500 g, 4°C, 15 min) in order to obtain citrated platelet-poor plasma used in the prothrombin time (PT) and activated partial thromboplastin clotting time (aPTT) assays at 37°C; for each assay, 190 μ l of platelet-poor plasma was incubated at 37°C with 10 μ l of sample [1 – saline solution, 2 – varespladib (1 mM) or 3 – antivenom (antivenom: venom ratio 1:3 'v/w'), 4 – *L. m. rhombeata* venom (1 mg/ml), 5 – *L. m. rhombeata* venom + VPL, 6 – *L. m. rhombeata* venom +



antivenom, 7 – and *L. m. rhombeata* venom + VPL + antivenom]. Antivenom:venom ratio was based on the manufacturer's stated neutralizing capacity for the antivenom, where 1 ml of antivenom neutralizes 3 mg of *L. muta* venom (Instituto Butantan, São Paulo, SP, Brazil). The minimum effective dose of varespladib (1 mM) was confirmed in pilot experiments. Protocols: 1 – *L. m. rhombeata* venom was pre-incubated with VPL and/or antivenom for 30 min at 37°C before PT- and aPTT-required clot formation recording; 2 – *L. m. rhombeata* venom was directly exposed to VPL and/or antivenom and followed by immediate PT- and aPTT-required clot formation recording.




FIGURE 2 | Action of varespladib on the procoagulant activity of *L. m. rhombeata* venom in rat citrated plasma *in vitro*. **(A)** Antivenom did not prevent the venom-induced procoagulant action applying the pre-incubation protocol, whereas varespladib alone avoided the procoagulant action for PT and its association with antivenom successfully prevented both intrinsic and extrinsic disorders. **(B)** Antivenom did not prevent the venom-induced procoagulant action applying the direct exposure protocol, whereas varespladib alone or combined with antivenom produced minor protective action on both coagulant pathways even combined with antivenom. Bars represent the mean \pm SDM ($n = 6$). $\blacklozenge p < 0.05$ compared to control, $\circ p < 0.05$ compared to venom alone and $* p < 0.05$ compared to antivenom alone.

Haemorrhagic Activity

Hemorrhagic activity was performed according to (Theakston and Reid, 1983). Male Wistar rats were anesthetized with sodium thiopental (1.8 mg/kg, i.p.) and their dorsal region was trichotomized in order to set the injection sites. Initially, some doses of *L. m. rhombeata* venom (0.01, 0.05, 0.1, 0.5 and 1 mg/kg) were tested in order to find the minimum haemorrhagic dose (0.5 mg/kg), which was used to investigate the neutralizing action of antivenom (antivenom:venom ratio of 1:3 'v/w') and varespladib (1 mM). Protocol: after injection of venom (i.d.), the animals were subsequently treated with antivenom and/or varespladib via an intraperitoneal injection, followed by monitoring period of 24 h. Control sites were injected with 0.9% NaCl, DMSO (varespladib

solvent) or antivenom. After 24 h, the rats were euthanized in saturated atmosphere with CO₂, the dorsal skin was removed and the subcutaneous hemorrhagic halos in the inner surface were measured through ImageJ software (National Institute of Health, Bethesda, Maryland, United States).

Statistical Analysis

All results (enzymatic, coagulant and haemorrhagic) were expressed as the mean \pm SDM and statistical comparisons were done using Student's *t* test or ANOVA followed by the Tukey-Kramer test, with $p < 0.05$ indicating significance. Data were analyzed using SAS University Edition software (SAS Institute Inc., Cary, NC, United States).


RESULTS

Inhibitory Action of Varespladib on the Main Enzymatic Groups of *L. m. rhombeata* Venom

In colorimetric assays, *L. m. rhombeata* (1 mg/ml) exhibited moderate enzymatic activity for PLA₂ which was promptly abolished from 0.01 mM of varespladib; the lowest concentration of varespladib (0.001 mM) did not produce inhibitory effect on the PLA₂ activity of this venom (Figure 1A). Caseinolytic (Figure 1B) and esterase (Figure 1C) activities were not affected by any of these concentrations of varespladib tested on artificial substrates (0.001–1 mM).

Inhibitory Action of Varespladib on the Coagulant Effect of *L. m. rhombeata* Venom in Rat Citrated Plasma

In rat citrated plasma, *L. m. rhombeata* venom (1 mg/ml) exhibited procoagulant action on the aPPT (intrinsic pathway) and PT (extrinsic pathway), decreasing in approximately 56.5 and 55.7% these times, respectively ($p < 0.05$ compared to basal values for both, $n = 6$) (Figures 2A,B). *L. m. rhombeata* venom (1 mg/ml)-induced procoagulant action (aPTT and PT) was not prevented by pre-incubating venom with antivenom (antivenom:venom ratio of 1:3 'v/w') alone for 30 min at 37°C before clotting assay; however, varespladib (1 mM) alone significantly prevented the venom-induced procoagulant action for PT, with approximately 16.4% of decreasing being verified ($p < 0.05$ compared to venom alone, $n = 6$), and it partially avoided the venom-induced procoagulant action for aPTT, being observed approximately 26.9% of decreasing; the combination of both agents successfully contributed to avoid both intrinsic and extrinsic disorders in rat citrated plasma, resulting in 8.4 and 18.6% of decreasing for PT and aPTT, respectively ($p < 0.05$ compared to venom alone, $n = 6$) (Figure 2A). In assays



performed immediately after the exposure *L. m. rhombeata* venom (1 mg/ml) to antivenom (antivenom:venom ratio of 1:3 'v/w') and/or varespladib (1 mM), both of agents slightly delayed the *L. m. rhombeata* venom (1 mg/ml)-induced procoagulant action for PT and aPTT; under this experimental condition, varespladib alone or combined with antivenom were more effective in avoiding only the venom-induced procoagulant action for PT, with approximately 23.3% of decreasing being verified using both agents (Figure 2B).

Inhibitory Action of Varespladib on the *L. m. rhombeata* Venom-Induced Subcutaneous Haemorrhage in Rat

L. m. rhombeata venom at low doses (5, 50 and 100 µg/kg) did not produce subcutaneous haemorrhagic action in rats, however, with exceptionally one animal exhibiting ~213 mm² of haemorrhagic halo for 50 µg of venom/kg (opened arrow) and another one ~301 mm² for 100 µg of venom/kg (filled arrow); the higher dose of this venom (500 µg/kg) induced pronounced haemorrhagic halo formation ($p < 0.05$ compared to control saline, n = 6) (Figure 3A). Antivenom (antivenom:venom ratio of 1:3 'v/w') administered (i.p) immediately after intradermic injections of *L. m. rhombeata* venom (500 µg/kg) was not able to prevent the venom-induced subcutaneous haemorrhage; varespladib (1 mM) alone or associated with antivenom (antivenom:venom ratio of 1:3 'v/w') exhibited a mild protective effect on the venom-induced subcutaneous haemorrhage (Figure 3B).

DISCUSSION

Envenomations by Viperidae snakes comprise a serious public health problem in Latin America (Chippaux, 2017; Ochoa-Avilés et al., 2020; Gutiérrez et al., 2020b). In Brazil, these snakes are represented by three main genera, i.e., *Bothrops*, *Crotalus* and *Lachesis* (Viperidae–Crotalinae), being responsible for more than 20,000 cases of snakebites per year in this country, as reported by Notifiable Diseases Information System of the Brazilian Ministry of Health (SINAN, Brasília, DF, Brazil). *Lachesis* snakes found in South America (*L. muta muta* and *L. m. rhombeata*) occasionally cause severe human envenomations (Magalhães et al., 2019; Diniz-Sousa et al., 2020), which are characterized by pronounced local and systemic disorders, e.g., necrosis (Damico et al., 2006; Ferreira et al., 2009; Damico et al., 2012), haemorrhage, coagulopathy (Sánchez et al., 1987; Sánchez et al., 1991; Sánchez et al., 1995; Fuly et al., 1997; Rucavado et al., 1999; Estêvão-Costa et al., 2000; Torres-Huaco et al., 2013) and hypotension (Dias et al., 2016a; Dias et al., 2016b), strongly associated with a variety of enzymatically active proteins such as snake venom metalloproteases, serine proteases, PLA₂, C-type lectins and L-amino acid oxidases (Weinberg et al., 2004; Junqueira-de-Azevedo et al., 2006; Bregge-Silva et al., 2012; Madrigal et al., 2012; Cordeiro et al., 2018; Diniz-Sousa et al., 2018; Wiesel et al., 2019) present in these venoms.

In recent years, the PLA₂ antagonistic activity of varespladib (Lewin et al., 2016; Salvador et al., 2019; Salvador et al., 2021), a synthetic drug developed to treat disturbances of inflammatory cascades associated with high levels of secreted PLA₂ (Varespladib, 2011), has been experimentally explored as an useful therapeutic alternative to complement antivenom therapies applied in envenomations by Elapidae and Viperidae snakes, with potential even to replace them in special situations in which these antivenoms are not available. Varespladib has high efficacy to suppress the systemic effects caused by several venoms from Elapidae (Lewin et al., 2016; Bittenbinder et al., 2018; Lewin et al., 2018; Wang et al.,

2018; Oliveira et al., 2020; Gutiérrez et al., 2020a; Dashevsky et al., 2021; Kazandjian et al., 2021; Silva-Carvalho et al., 2021) and Viperidae (Lewin et al., 2016; Wang et al., 2018; Youngman et al., 2020; Zinenko et al., 2020; Gutiérrez et al., 2020a; Liu et al., 2021) snakes. However, there is no report associating the efficacy of varespladib with toxicological aspects of *Lachesis* venoms.

Based on this premise, we have unprecedentedly investigated the action of varespladib on the enzymatic, coagulant and haemorrhagic activities of *Lachesis muta rhombeata* venom to determine its efficiency as a single pharmacological tool or combined with a commercial antivenom used in Brazil. In summary, we have demonstrated that varespladib used as a single pharmacological tool abolishes the PLA₂ activity of *L. m. rhombeata* venom at low concentrations, without affecting the catalytic activity for proteases (metalloprotease and serino protease) of the venom, indicating a very specific inhibitory activity; its high PLA₂ antagonistic activity was reflected on the venom-induced procoagulant action, mostly interfering on the extrinsic pathway disorders produced by venom in rat citrated serum (pre-incubation protocol), whereas the drug did not prevent the haemorrhagic activity induced by *L. m. rhombeata* venom in rats. The association of varespladib with a commercial antivenom used in Brazil to treat envenomations by *Lachesis* spp. did not produce important synergic actions on the procoagulant (direct incubation protocol) and haemorrhagic effects induced by *L. m. rhombeata* venom; such interaction resulted in a major prevention of the venom-induced intrinsic and extrinsic coagulant disorders seen under pre-incubation protocol.

Although the procoagulant action of Viperidae venoms has been mostly associated with the presence of serine proteases in these venoms (Gutiérrez et al., 2021), varespladib can partially prevent the procoagulant action of *L. m. rhombeata* venom, indicating an eventual role of PLA₂ in these processes. Accordingly, varespladib also contributes to prevent coagulating disorders induced by other groups of snake venoms, e.g., *Bothrops* (Viperidae-Crotalinae), *Daboia*, *Echis*, *Oxyuranus*, *Naja*, *Pseudechis* and *Bitis* spp., which exhibit high PLA₂ activity (Bittenbinder et al., 2018; Xie et al., 2020; Youngman et al., 2020; Zdenek et al., 2020). On the other hand, varespladib does not affect the *L. m. rhombeata* venom-induced subcutaneous haemorrhage in rats, reflecting its disability in antagonizing the metalloproteases of this venom, since local and systemic haemorrhagic actions produced by Viperidae venoms are mainly mediated by this family of toxins (Escalante et al., 2011; Seo et al., 2017). In addition, although an Asp49 PLA₂ (LmrTX) with anticoagulant activity has been already isolated from *L. m. rhombeata* venom (Damico et al., 2012), it does not appear to contribute expressively with the subcutaneous haemorrhage induced in rats, as reported in this study.

L. m. rhombeata venom has been an important object of study for structural characterization of toxins such as metalloproteases (Cordeiro et al., 2018), serine proteases (Aguilar et al., 1996; Wiezel et al., 2019), C-type lectins (Wiezel et al., 2019), basic and acid PLA₂ (Damico et al., 2012; Cordeiro et al., 2015; Diniz-Sousa et al., 2018), phospholipase B and hyaluronidase (Wiezel et al., 2015), including bradykinin-potentiating peptides (BPPs) (Pinheiro-Júnior et al., 2018). As previously commented, these toxins are responsible by developing the main toxicological

aspects of the envenomation by *Lachesis*. However, the factual involvement of PLA₂ toxins on the effects produced by *Lachesis* venoms have been poorly investigated, with a few reports describing their inhibitory action of platelet aggregation (Cordeiro et al., 2015), anticoagulant and antithrombotic activities (Damico et al., 2012), and cytotoxicity on C2C12 myotubes (Diniz-Sousa et al., 2018).

In Brazil, envenomations by *L. m. muta* and *L. m. rhombeata* are treated with anti-*Bothrops/Lachesis* serums, with their rescue action being dependent on early i.v. administration (Pla et al., 2013; Madrigal et al., 2017; Solano et al., 2018). There are some negative factors that resulting in deaths by accidents involving *Lachesis* snakes in Brazil: 1) limited availability of antivenoms, 2) difficulties in accessing health services in certain regions of the country, and 3) lack of a specific anti-*Lachesis* serum. Consequently, other types of antivenoms, e.g., anti-*Bothrops* serum and anti-*Bothrops/Crotalus* serum, have been inaccurately recommended to treat envenomations by *L. muta* in the absence of anti-*Bothrops/Lachesis* serum (Magalhães et al., 2019; Muniz et al., 2021). These challenges involving the treatment of envenomations by *Lachesis* snakes strengthen the search for therapeutically useful adjuncts, with varespladib rising as a plausible tool.

In conclusion, varespladib abolishes efficiently the PLA₂ activity of *L. m. rhombeata* venom at low concentrations and does not affect other majority enzymatic groups of this venom, e.g., metalloproteases and serine proteases. Varespladib alone might partially prevent the procoagulant effect of *L. m. rhombeata* venom, with its combination with antivenom avoiding alterations in both intrinsic and extrinsic pathways. Varespladib does not reduce the subcutaneous haemorrhage formation induced by *L. m. rhombeata* venom in rats due to the lack of inhibitory action on the proteases of the venom. The association of varespladib with a recommended polyvalent antivenom does not produce synergic action on the venom-induced haemorrhagic action but it helps to prevent the venom-induced coagulation disorders.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the Article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by the Committee for Ethics in Animal Use of University of Western São Paulo (CEUA/UNOESTE, Protocol No. 6713/2021).

AUTHOR CONTRIBUTIONS

RMBN and RSF contributed to conception and design of the study. PGG, DRP, and NLV organized the database. LFA performed the statistical analysis. PGG, DRP, and KAT-B wrote the first draft of the manuscript. NJSJ and SH wrote

sections of the manuscript. KM-Z, EGR, and RSF contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This work was funded by institutional resources from University of Western São Paulo (UNOESTE, Presidente Prudente, SP, Brazil) and Fundação de Amparo à Pesquisa

do Estado de São Paulo (FAPESP, São Paulo, SP, Brazil, Grant No. 2020/04287-6 and 2021/14375-2). PGG was also supported by a studentship from FAPESP (Grant No. 2020/11268-8). NJSJ and SH are supported by a research fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brasília, DF, Brazil, Grant Nos. 309320/2016-0 and 310547/2014-8, respectively).

REFERENCES

- Aguiar, A. S., Alves, C. R., Melgarejo, A., and Giovanni-De-Simone, S. (1996). Purification and Partial Characterization of a Thrombin-Like/gyroxin Enzyme from Bushmaster (*Lachesis muta Rhombeata*) Venom. *Toxicon* 34 (5), 555–565. doi:10.1016/0041-0101(95)00159-X
- Bittenbinder, M. A., Zdenek, C. N., Op den Brouw, B., Youngman, N. J., Dobson, J. S., Naude, A., et al. (2018). Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting *Naja* Venoms that Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib). *Toxins (Basel)* 10 (12), E516. doi:10.3390/toxins10120516
- Bregge-Silva, C., Nonato, M. C., de Albuquerque, S., Ho, P. L., Junqueira de Azevedo, I. L., Vasconcelos Diniz, M. R., et al. (2012). Isolation and Biochemical, Functional and Structural Characterization of a Novel L-Amino Acid Oxidase from *Lachesis muta* Snake Venom. *Toxicon* 60 (7), 1263–1276. doi:10.1016/j.toxicon.2012.08.008
- Bryan-Quirós, W., Fernández, J., Gutiérrez, J. M., Lewin, M. R., and Lomonte, B. (2019). Neutralizing Properties of LY315920 toward Snake Venom Group I and II Myotoxic Phospholipases A₂. *Toxicon* 157, 1–7. doi:10.1016/j.toxicon.2018.11.292
- Chippaux, J. P. (2017). Snakebite Envenomation Turns Again into a Neglected Tropical Disease!. *J. Venom. Anim. Toxins Incl. Trop. Dis.* 23, 38–42. doi:10.1186/s40409-017-0127-6
- Carregari, V. C., Stuaní Floriano, R., Rodrigues-Simioni, L., Winck, F. V., Baldasso, P. A., Ponce-Soto, L. A., et al. (2013). Biochemical, Pharmacological, and Structural Characterization of New Basic PLA₂ Bbil-TX from Bothriopsis Bilineata Snake Venom. *Biomed. Res. Int.* 2013, 612649. doi:10.1155/2013/612649
- Cordeiro, F. A., Coutinho, B. M., Wiesel, G. A., de Castro Figueiredo Bordon, K., Bregge-Silva, C., Rosa-Garzon, N. G., et al. (2018). Purification and Enzymatic Characterization of a Novel Metalloprotease from *Lachesis muta Rhombeata* Snake Venom. *J. Venom. Anim. Toxins Incl. Trop. Dis.* 24, 32. doi:10.1186/s40409-018-0171-x
- Cordeiro, F. A., Perini, T. G., Bregge-Silva, C., Cremonese, C. M., Rodrigues, R. S., Boldrini-França, J., et al. (2015). A New Phospholipase A₂ from *Lachesis muta Rhombeata*: Purification, Biochemical and Comparative Characterization with Crotoxin B. *Protein Pept. Lett.* 22 (9), 816–827. doi:10.2174/0929866522666150706112431
- Costa, H. C., and Bérnils, R. S. (2018). Répteis Do Brasil e suas Unidades Federativas: Lista de espécies. *Herpetologia Brasileira* 8, 11–57.
- Damico, D. C., Bueno, L. G., Rodrigues-Simioni, L., Marangoni, S., da Cruz-Höfling, M. A., and Novello, J. C. (2006). Functional Characterization of a Basic D49 Phospholipase A₂ (LmTX-I) from the Venom of the Snake *Lachesis muta Muta* (Bushmaster). *Toxicon* 47 (7), 759–765. doi:10.1016/j.toxicon.2006.02.007
- Damico, D. C., Nascimento, J. M., Lomonte, B., Ponce-Soto, L. A., Joazeiro, P. P., Novello, J. C., et al. (2007). Cytotoxicity of *Lachesis muta Muta* Snake (Bushmaster) Venom and its Purified Basic Phospholipase A₂ (LmTX-I) in Cultured Cells. *Toxicon* 49 (5), 678–692. doi:10.1016/j.toxicon.2006.11.014
- Damico, D. C., Vassequi-Silva, T., Torres-Huaco, F. D., Nery-Diez, A. C., de Souza, R. C., Da Silva, S. L., et al. (2012). LmrTX, a Basic PLA₂ (D49) Purified from *Lachesis muta Rhombeata* Snake Venom with Enzymatic-Related Antithrombotic and Anticoagulant Activity. *Toxicon* 60 (5), 773–781. doi:10.1016/j.toxicon.2012.06.010
- Dashevsky, D., Bénard-Valle, M., Neri-Castro, E., Youngman, N. J., Zdenek, C. N., Alagón, A., et al. (2021). Anticoagulant *Micrurus* Venoms: Targets and Neutralization. *Toxicol. Lett.* 337, 91–97. doi:10.1016/j.toxlet.2020.11.010
- Dias, L., Rodrigues, M. A., Inoue, B. R., Rodrigues, R. L., Rennó, A. L., de Souza, V. B., et al. (2016a). Pharmacological Analysis of Hemodynamic Responses to *Lachesis muta* (South American Bushmaster) Snake Venom in Anesthetized Rats. *Toxicon* 123, 25–44. doi:10.1016/j.toxicon.2016.10.002
- Dias, L., Rodrigues, M. A., Rennó, A. L., Stroka, A., Inoue, B. R., Panunto, P. C., et al. (2016b). Hemodynamic Responses to *Lachesis muta* (South American Bushmaster) Snake Venom in Anesthetized Rats. *Toxicon* 123, 1–14. doi:10.1016/j.toxicon.2016.10.001
- Diniz, M. R., and Oliveira, E. B. (1992). Purification and Properties of a Kininogenin from the Venom of *Lachesis muta* (Bushmaster). *Toxicon* 30 (3), 247–258. doi:10.1016/0041-0101(92)90867-5
- Diniz-Sousa, R., Caldeira, C. A. S., Kayano, A. M., Paloschi, M. V., Pimenta, D. C., Simões-Silva, R., et al. (2018). Identification of the Molecular Determinants of the Antibacterial Activity of LmutTX, a Lys49 Phospholipase A₂ Homologue Isolated from *Lachesis muta muta* Snake Venom (Linnaeus, 1766). *Basic Clin. Pharmacol. Toxicol.* 122 (4), 413–423. doi:10.1111/bcpt.12921
- Diniz-Sousa, R., Moraes, J. D. N., Rodrigues-da-Silva, T. M., Oliveira, C. S., and Caldeira, C. A. D. S. (2020). A Brief Review on the Natural History, Venomics and the Medical Importance of Bushmaster (*Lachesis*) Pit viper Snakes. *Toxicon X* 7 (7), 100053. doi:10.1016/j.toxx.2020.100053
- Erlanger, B. F., Kokowsky, N., and Cohen, W. (1961). The Preparation and Properties of Two New Chromogenic Substrates of Trypsin. *Arch. Biochem. Biophys.* 95 (2), 271–278. doi:10.1016/0003-9861(61)90145-x
- Escalante, T., Rucavado, A., Fox, J. W., and Gutiérrez, J. M. (2011). Key Events in Microvascular Damage Induced by Snake Venom Hemorrhagic Metalloproteinases. *J. Proteomics* 74 (9), 1781–1794. doi:10.1016/j.jprot.2011.03.026
- Estêvão-Costa, M. I., Diniz, C. R., Magalhães, A., Markland, F. S., and Sanchez, E. F. (2000). Action of Metalloproteinases Mutalysin I and II on Several Components of the Hemostatic and Fibrinolytic Systems. *Thromb. Res.* 99 (4), 363–376. doi:10.1016/s0049-3848(00)00259-0
- Ferreira, T., Camargo, E. A., Ribela, M. T., Damico, D. C., Marangoni, S., Antunes, E., et al. (2009). Inflammatory Oedema Induced by *Lachesis muta muta* (Surucucu) Venom and LmTX-I in the Rat Paw and Dorsal Skin. *Toxicon* 53 (1), 69–77. doi:10.1016/j.toxicon.2008.10.016
- Fuly, A. L., Calil-Elias, S., Martinez, A. M., Melo, P. A., and Guimarães, J. A. (2003). Myotoxicity Induced by an Acidic Asp-49 Phospholipase A₂ Isolated from *Lachesis muta* Snake Venom. Comparison with Lysophosphatidylcholine. *Int. J. Biochem. Cell Biol.* 35 (10), 1470–1481. doi:10.1016/s1357-2725(03)00129-8
- Fuly, A. L., Calil-Elias, S., Zingali, R. B., Guimarães, J. A., and Melo, P. A. (2000). Myotoxic Activity of an Acidic Phospholipase A₂ Isolated from *Lachesis muta* (Bushmaster) Snake Venom. *Toxicon* 38 (7), 961–972. doi:10.1016/s0041-0101(99)00208-1
- Fuly, A. L., Machado, O. L., Alves, E. W., and Carlini, C. R. (1997). Mechanism of Inhibitory Action on Platelet Activation of a Phospholipase A₂ Isolated from *Lachesis muta* (Bushmaster) Snake Venom. *Thromb. Haemost.* 78 (5), 1372–1380. doi:10.1055/s-0038-1665414
- Giovanni-De-Simone, S., Aguiar, A. S., Gimenez, A. R., Novellino, K., and de Moura, R. S. (1997). Purification, Properties, and N-Terminal Amino Acid Sequence of a Kallikrein-like Enzyme from the Venom of *Lachesis muta Rhombeata* (Bushmaster). *J. Protein Chem.* 16 (8), 809–818. doi:10.1023/a:1026372018547
- Graham, R. L., Graham, C., McClean, S., Chen, T., O'Rourke, M., Hirst, D., et al. (2005). Identification and Functional Analysis of a Novel Bradykinin Inhibitory Peptide in the Venoms of New World Crotalinae Pit Vipers. *Biochem. Biophys. Res. Commun.* 338 (3), 1587–1592. doi:10.1016/j.bbrc.2005.10.130

- Gutiérrez, J. M., Albuлесcu, L.-O., Clare, R. H., Casewell, N. R., Abd El-Aziz, T. M., Escalante, T., et al. (2021). The Search for Natural and Synthetic Inhibitors that Would Complement Antivenoms as Therapeutics for Snakebite Envenoming. *Toxins* 13 (7), 451. doi:10.3390/toxins13070451
- Gutiérrez, J. M., Lewin, M. R., Williams, D. J., and Lomonte, B. (2020a). Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. *Toxins (Basel)* 12 (2), 131. doi:10.3390/toxins12020131
- Gutiérrez, J. M., Castillo, L., de Naves, K. M. D., Masis, J., and Alape-Girón, A. (2020b). Epidemiology of Snakebites in El Salvador (2014-2019). *Toxicon* 186, 26–28. doi:10.1016/j.toxicon.2020.07.027
- Junqueira-de-Azevedo, I. L., Ching, A. T., Carvalho, E., Faria, F., Nishiyama, M. Y., Jr, Ho, P. L., et al. (2006). Lachesis muta (Viperidae) cDNAs Reveal Diverging Pit viper Molecules and Scaffolds Typical of Cobra (Elapidae) Venoms: Implications for Snake Toxin Repertoire Evolution. *Genetics* 173, 877–889. doi:10.1534/genetics.106.056515
- Kazandjian, T. D., Arrahman, A., Still, K. B. M., Somsen, G. W., Vonk, F. J., Casewell, N. R., et al. (2021). Anticoagulant Activity of *Naja nigricollis* Venom Is Mediated by Phospholipase A₂ Toxins and Inhibited by Varespladib. *Toxins (Basel)* 13, 302. doi:10.3390/toxins13050302
- Lewin, M., Samuel, S., Merkel, J., and Bickler, P. (2016). Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A₂ and a Possible Pre-referral Treatment for Envenomation. *Toxins (Basel)* 8 (9), 248. doi:10.3390/toxins8090248
- Lewin, M. R., Gilliam, L. L., Gilliam, J., Samuel, S. P., Bulfone, T. C., Bickler, P. E., et al. (2018). Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and rescue Juvenile Pigs from Lethal Doses of *Micrurus fulvius* (Eastern Coral Snake) Venom. *Toxins (Basel)* 10 (11), E479. doi:10.3390/toxins10110479
- Liu, C. C., Wu, C. J., Hsiao, Y. C., Yang, Y. H., Liu, K. L., Huang, G. J., et al. (2021). Snake Venom Proteome of *Protobothrops mucrosquamatus* in Taiwan: Delaying Venom-Induced Lethality in a Rodent Model by Inhibition of Phospholipase A₂ Activity with Varespladib. *J. Proteomics* 234, 104084. doi:10.1016/j.jpropt.2020.104084
- Madrigal, M., Pla, D., Sanz, L., Barboza, E., Arroyo-Portilla, C., Corrêa-Netto, C., et al. (2017). Cross-reactivity, Antivenomics, and Neutralization of Toxic Activities of Lachesis Venoms by Polyspecific and Monospecific Antivenoms. *Plos Negl. Trop. Dis.* 11 (8), e0005793. doi:10.1371/journal.pntd.0005793
- Madrigal, M., Sanz, L., Flores-Díaz, M., Sasa, M., Núñez, V., Alape-Girón, A., et al. (2012). Snake Venomics across Genus Lachesis. Ontogenetic Changes in the Venom Composition of Lachesis Stenophrys and Comparative Proteomics of the Venoms of Adult Lachesis Melanocephala and Lachesis Acrochorda. *J. Proteomics* 77, 280–297. doi:10.1016/j.jpropt.2012.09.003
- Magalhães, S. F. V., Peixoto, H. M., Moura, N., Monteiro, W. M., and de Oliveira, M. R. F. (2019). Snakebite Envenomation in the Brazilian Amazon: a Descriptive Study. *Trans. R. Soc. Trop. Med. Hyg.* 113, 143–151. doi:10.1093/trstmh/try121
- Muniz, E. G., Noronha, M. D. D. N., Saraiva, M. D. G. G., Monteiro, W. M., and Oliveira, S. S. (2021). Neutralization of Hemostatic Disorders Induced by Lachesis muta Venom using Brazilian Antivenoms. *Toxicon* 191, 44–47. doi:10.1016/j.toxicon.2020.12.013
- Nogueira, C. C., Argôlo, A. J. S., Arzamendia, V., Azevedo, J. A., Barbo, F. E., Bérnils, R. S., et al. (2019). Atlas of Brazilian Snakes: Verified point-locality Maps to Mitigate the Wallacean Shortfall in a Megadiverse Snake Fauna. *South. Am. J. Herpetol.* 14 (1), 1–274. doi:10.2994/sajh-d-19-00120.1
- Ochoa-Avilés, A., Heredia-Andino, O. S., Escandón, S. A., Celorio-Carvajal, C. A., Arias-Peláez, M. C., Zaruma-Torres, F., et al. (2020). Viperidae Snakebites in Ecuador: a Review of Epidemiological and Ecological Aspects. *Toxicon X* 7, 100051. doi:10.1016/j.toxcx.2020.100051
- Oliveira, I. C. F., Gutiérrez, J. M., Lewin, M. R., and Oshima-Franco, Y. (2020). Varespladib (LY315920) Inhibits Neuromuscular Blockade Induced by Oxyuranus Scutellatus Venom in a Nerve-Muscle Preparation. *Toxicon* 187, 101–104. doi:10.1016/j.toxicon.2020.08.023
- Pinheiro-Júnior, E. L., Boldrini-França, J., de Campos Araújo, L. M. P., Santos-Filho, N. A., Bendhack, L. M., Cilli, E. M., et al. (2018). LmrPPP9: A Synthetic Bradykinin-Potentiating Peptide from Lachesis muta Rhombeata Venom that Inhibits the Angiotensin-Converting Enzyme Activity *in vitro* and Reduces the Blood Pressure of Hypertensive Rats. *Peptides* 102, 1–7. doi:10.1016/j.peptides.2018.01.015
- Pla, D., Sanz, L., Molina-Sánchez, P., Zorita, V., Madrigal, M., Flores-Díaz, M., et al. (2013). Snake Venomics of Lachesis muta Rhombeata and Genus-wide Antivenomics Assessment of the Paraspecific Immunoreactivity of Two Antivenoms Evidence the High Compositional and Immunological Conservation across Lachesis. *J. Proteomics* 89, 112–123. doi:10.1016/j.jpropt.2013.05.028
- Rucavado, A., Flores-Sánchez, E., Franceschi, A., Magalhaes, A., and Gutiérrez, J. M. (1999). Characterization of the Local Tissue Damage Induced by LHF-II, a Metalloproteinase with Weak Hemorrhagic Activity Isolated from Lachesis muta muta Snake Venom. *Toxicon* 37 (9), 1297–1312. doi:10.1016/s0041-0101(98)00268-2
- Salvador, G. H. M., Borges, R. J., Lomonte, B., Lewin, M. R., and Fontes, M. R. M. (2021). The Synthetic Varespladib Molecule Is a Multi-Functional Inhibitor for PLA2 and PLA2-like Ophidic Toxins. *Biochim. Biophys. Acta Gen. Subj* 1865 (7), 129913. doi:10.1016/j.bbagen.2021.129913
- Salvador, G. H. M., Gomes, A. A. S., Bryan-Quirós, W., Fernández, J., Lewin, M. R., Gutiérrez, J. M., et al. (2019). Structural Basis for Phospholipase A₂-like Toxin Inhibition by the Synthetic Compound Varespladib (LY315920). *Sci. Rep.* 9 (1), 17203. doi:10.1038/s41598-019-53755-5
- Sánchez, E. F., Costa, M. I., Chavez-Olortegui, C., Assakura, M. T., Mandelbaum, F. R., and Diniz, C. R. (1995). Characterization of a Hemorrhagic Factor, LHF-I, Isolated from the Bushmaster Snake (*Lachesis muta muta*) Venom. *Toxicon* 33 (12), 1653–1667. doi:10.1016/0041-0101(95)00097-6
- Sánchez, E. F., Magalhães, A., Mandelbaum, F. R., and Diniz, C. R. (1991). Purification and Characterization of the Hemorrhagic Factor II from the Venom of the Bushmaster Snake (*Lachesis muta muta*). *Biochim. Biophys. Acta* 1074 (3), 347–356. doi:10.1016/0304-4165(91)90084-t
- Sánchez, E. F., Magalhães, A., and Diniz, C. R. (1987). Purification of a Hemorrhagic Factor (LHF-I) from the Venom of the Bushmaster Snake, *Lachesis muta muta*. *Toxicon* 25 (6), 611–619. doi:10.1016/0041-0101(87)90107-3
- Sanz, L., Escolano, J., Ferretti, M., Biscoglio, M. J., Rivera, E., Crescenti, E. J., et al. (2008). Snake Venomics of the South and Central American Bushmasters. Comparison of the Toxin Composition of Lachesis muta Gathered from Proteomic versus Transcriptomic Analysis. *J. Proteomics* 71 (1), 46–60. doi:10.1016/j.jpropt.2007.10.004
- Seo, T., Sakon, T., Nakazawa, S., Nishioka, A., Watanabe, K., Matsumoto, K., et al. (2017). Haemorrhagic Snake Venom Metalloproteases and Human ADAMs Cleave LRP5/6, Which Disrupts Cell-Cell Adhesions *in vitro* and Induces Haemorrhage *in vivo*. *FEBS J.* 284 (11), 1657–1671. doi:10.1111/febs.14066
- Silva-Carvalho, R., Gaspar, M. Z., Quadros, L. H. B., Lobo, L. G. G., Rogério, L. M., Santos, N. T. S., et al. (2021). *In Vivo* treatment with Varespladib, a Phospholipase A₂ Inhibitor, Prevents the Peripheral Neurotoxicity and Systemic Disorders Induced by *Micrurus corallinus* (Coral Snake) Venom in Rats. *Toxicol. Lett.* 356, 54–63. doi:10.1016/j.toxlet.2021.11.003
- Soares, M. R., Oliveira-Carvalho, A. L., Wermelinger, L. S., Zingali, R. B., Ho, P. L., Junqueira-de-Azevedo, I. L., et al. (2005). Identification of Novel Bradykinin-Potentiating Peptides and C-type Natriuretic Peptide from Lachesis muta Venom. *Toxicon* 46 (1), 31–38. doi:10.1016/j.toxicon.2005.03.006
- Solano, G., Gómez, A., Corrales, G., Chacón, D., Estrada, R., and León, G. (2018). Contributions of the Snake Venoms of Bothrops asper, Crotalus Simus and Lachesis Stenophrys to the Paraspecificity of the Central American Polyspecific Antivenom (PoliVal-ICP). *Toxicon* 144, 1–6. doi:10.1016/j.toxicon.2018.01.016
- Theakston, R. D., and Reid, H. A. (1983). Development of Simple Standard Assay Procedures for the Characterization of Snake Venom. *Bull World Health Organ.* 61 (6), 949–956.
- Torres-Bonilla, K. A., Panunto, P. C., Pereira, B. B., Zambrano, D. F., Herrán-Medina, J., Bernal, M. H., et al. (2020). Toxinological Characterization of Venom from Leptodeira annulata (Banded Cat-Eyed Snake; Dipsadidae, Imantodini). *Biochimie* 174, 171–188. doi:10.1016/j.biochi.2020.04.006
- Torres-Huaco, F. D., Werneck, C. C., Vicente, C. P., Vassequi-Silva, T., Nery-Diez, A. C., Mendes, C. B., et al. (2013). Rapid Purification and Procoagulant and Platelet Aggregating Activities of Rhombobin: a Thrombin-like/gyroxin-like Enzyme from Lachesis muta Rhombeata Snake Venom. *Biomed. Res. Int.* 2013, 903292. doi:10.1155/2013/903292

- Varespladib (2011). Varespladib. *Am. J. Cardiovasc. Drugs* 11:137–43. doi:10.2165/11533650-000000000-00000
- Wang, Y., Zhang, J., Zhang, D., Xiao, H., Xiong, S., and Huang, C. (2018). Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. *Molecules* 23 (2), E391. doi:10.3390/molecules23020391
- Weinberg, M. L., Felicori, L. F., Bello, C. A., Magalhães, H. P., Almeida, A. P., Magalhães, A., et al. (2004). Biochemical Properties of a Bushmaster Snake Venom Serine Proteinase (LV-Ka), and its Kinin Releasing Activity Evaluated in Rat Mesenteric Arterial Rings. *J. Pharmacol. Sci.* 96, 333–342. doi:10.1254/jphs.fj04005x
- Wiesel, G. A., Bordon, K. C., Silva, R. R., Gomes, M. S., Cabral, H., Rodrigues, V. M., et al. (2019). Subproteome of *Lachesis muta Rhombeata* Venom and Preliminary Studies on LmrSP-4, a Novel Snake Venom Serine Proteinase. *J. Venom. Anim. Toxins Incl. Trop. Dis.* 25, e147018. doi:10.1590/1678-9199-JVATITD-1470-18
- Wiesel, G. A., dos Santos, P. K., Cordeiro, F. A., Bordon, K. C., Selistre-de-Araújo, H. S., Ueberheide, B., et al. (2015). Identification of Hyaluronidase and Phospholipase B in *Lachesis muta Rhombeata* Venom. *Toxicon* 107 (Pt B), 359–368. doi:10.1016/j.toxicon.2015.08.029
- Xie, C., Albulescu, L. O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., et al. (2020). Varespladib Inhibits the Phospholipase A₂ and Coagulopathic Activities of Venom Components from Hemotoxic Snakes. *Biomedicines* 8 (6), 165. doi:10.3390/biomedicines8060165
- Youngman, N. J., Walker, A., Naude, A., Coster, K., Sundman, E., and Fry, B. G. (2020). Varespladib (LY315920) Neutralises Phospholipase A₂ Mediated Prothrombinase-Inhibition Induced by Bitis Snake Venoms. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 236, 108818. doi:10.1016/j.cbpc.2020.108818
- Zdenek, C. N., Youngman, N. J., Hay, C., Dobson, J., Dunstan, N., Allen, L., et al. (2020). Anticoagulant Activity of Black Snake (Elapidae: Pseudechis) Venoms: Mechanisms, Potency, and Antivenom Efficacy. *Toxicol. Lett.* 330, 176–184. doi:10.1016/j.toxlet.2020.05.014
- Zinenko, O., Tovstukha, I., and Korniyenko, Y. (2020). PLA₂ Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's viper *Vipera berus* *Nikolskii*. *Toxins (Basel)* 12 (6), 356. doi:10.3390/toxins12060356

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gutierrez, Pereira, Vieira, Arantes, Silva, Torres-Bonilla, Hyslop, Morais-Zani, Nogueira, Rowan and Floriano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.